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INDUSTRY MARKET SEGMENT- RESPIRATORY/
ANTI-INFECTIVES 
•  Market Segments include Cardiovascular, Central 
Nervous System, Internal Medicine, Oncology, 
Respiratory/Anti-Infectives, Consumer Products, and 
Other.  
•  Anti-Infectives include Antibiotics, Antivirals and 
Vaccines, while Respiratory includes drugs that are 
medicines for conditions and diseases relating to the 
lungs and/or breathing.  
•  Johnson & Johnson: Remicade (Rheumatoid 
Arthritis), Velcade (Multiple Myeloma and Mantle 
Cell Lymphoma); Risperdal Consta (Schizophrenia)  
•  Pfizer: Lyrica (Epilepsy), Lipitor (LDL cholesterol 
reduction), Enbrel (Rheumatoid, Juvenile 
Rheumatoid and Psoriatic Arthritis) 
•  Novartis AG: Gleevec (Chronic Myeloid Leukemia) 
Diovan/Co-Diovan (Hypertension), Lucentis,(Age-
related macular degeneration) Sandostatin 
(Acromegaly) 
•  Roche: MabThera/Rituxan (non-Hodgkin’s 
Lymphoma), Herceptin (HER2-positive Breast 
Cancer), Avastin (Colorectal Cancer) 
•  Bayer AG: Betaferon (Multiple Sclerosis), Kogenate 
(Hemophilia), Nexavar (Kidney/Liver Cancer) 
TOP 5 COMPETITORS (2012) 
Source: “Abbott Laboratories: Income Statement – All 
Available Years.” Mergent Online. Web 6 July 2013.  
“AstraZeneca Plc: Income Statement – All Available 
Years.” Mergent Online. Web 6 July 2013. 
“Bayer AG: Income Statement – All Available Years.” 
Mergent Online. Web 6 July 2013. 
“Bristol-Meyers Squibb Co.: Income Statement – All 
Available Years.” Mergent Online. Web. 6 July 2013. 
“GlaxoSmithKline Plc: Income Statement – All Available 
Years.” Mergent Online. Web 6 July 2013. 
“Johnson & Johnson: Income Statement – All Available 
Years.” Mergent Online. Web 6 July 2013. 
“Lilly (Eli) & Co: Income Statement – All Available Years.” 
Mergent Online. Web 6 July 2013. 
“Novartis AG Basel: Income Statement – All Available 
Years.” Mergent Online. Web 6 July 2013. 
“Merck & Co., Inc.: Income Statement – All Available 
Years.” Mergent Online. Web 6 July 2013. 
“Pfizer Inc: Income Statement – All Available Years.” 
Mergent Online. Web 6 July 2013. 
“Roche Holding Ltd.: Income Statement – All Available 
Years.” Mergent Online. Web 6 July 2013. 
“Sanofi: Income Statement – All Available Years.” Mergent 
Online. Web 6 July 2013. 
 
Industry Attractiveness uses 15 different criteria to determine whether 
investment in an Industry is wise.1 
•  The best-case scenario is to have a total score of 150 as it suggest 
that a company can handle all of the difficult forces.2  
•  Pharmaceutical Industry scored a 89.  
•  Biotechnology Industry scored a 103. 
•  Respiratory/Anti-Infectives Segment scored a 104.  
ANALYSIS OF INDUSTRY ATTRACTIVENESS AND 
COMPETITIVE ENVIRONMENT ANALYSIS 
 
1Mann, and Seshan- Strategy for the 21st Century, p.101-103, IBT Global, Edition 6 2012 
2Mann, and Seshan- Strategy for the 21st Century, p.101-103, IBT Global, Edition 6 2012   
ENVIRONMENTAL THREATS AND 
OPPORTUNITIES PROFILE: MERCK & CO, INC. 
RESPIRATORY/ANTI-INFECTIVES SEGMENT  
(2013)  
Most Impactful Threats: 
•  Competition  
•  Spirit/Ethics  
Most Impactful Opportunities 
•  Technology 
•  Social  
 
 
ENVIRONMENTAL THREATS AND OPPORTUNITIES PROFILE (ETOP): 
MERCK, RESPIRATORY/ANTI-INFECTIVES SEGMENT (2013) 
Source: Rowe, Alan, J.,  Mason, Richard O.,Dickel, Karl E., Mann, Richard B., Mockler. Robert J., Strategic  
Management- A Methodological Approach. 4th Ed. 1999, Reading, MA: Addison - Wesley. p.115.   
Mann and Seshan, Strategy for the 21st Century. IBT Global, Edition 6, 2012. p.75-81  
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Comments:(
)
The)Respiratory/Anti*Infective)Market)Segment)is)growing)based)on)new)
applications)of)Technology)to)create)innovative)products)addressing)anti*biotic)
resistant)diseases.)The)rise)in)elderly)patients)and)access)to)emerging)country)
markets)as)Social)Factors)open)new)opportunities)for)market)expansion.)Issues)
relating)to)FDA)approval)and)ethical)concerns)over)drug)trials)and)applications)of)
stem)cell)research)present)possible)road)blocks)in)the)development)of)the)
Segment.)The)dilution)of)the)Competition)in)the)Market)Segment)mitigates)the)
impact)of)that)factor.)Ultimately)innovative)uses)of)Technology)to)address)issues)
raised)by)Social)and)International)Factors)will)put)companies)like)Merck)ahead)in)
the)Market)Segment.))!
TECHNOLOGY IN THE PHARMACEUTICAL 
INDUSTRY 
•  Genomics  
•  Biotechnology  
•  Biomarkers 
Merck’s Focus:  
•  Anti-Inflammatory agents 
•  Biomarkers 
•  Vaccines 
MERCK: GAP ANALYSIS, RESPIRATORY/ 
ANTI-INFECTIVES SEGMENT (2012) !
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Source: Mann and Seshan, Strategy for the 21st Century. IBT Global, Edition 6, 2012. p.174  
TECHNOLOGY EVALUATION MATRIX: RESPIRATORY/
ANTI-INFECTIVES SEGMENT ($B) (2012)  
Source: Mann and Seshan, Strategy for the 21st Century. IBT Global, Edition 6, 2012. p.174  
§  Abbott Laboratories 
§  AstraZeneca Plc. 
§  Bayer AG 
§  Bristol-Myers Squibb Co. 
§  GlaxoSmithKline Plc. 
§  Johnson & Johnson 
§  Lilly (Eli) & Co. 
§  Merck & Co., Inc* 
§  Novartis AG Basel 
§  Pfizer Inc. 
§  Roche Holding Ltd. 
§  Sanofi 
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ENVIRONMENTAL THREATS AND 
OPPORTUNITIES PROFILE: ACQUISITION OF 
NOVAVAX, INC.  
Most Impactful Threats: 
•  Competition 
•  Politics 
Most Impactful Opportunities: 
•  Social  
•  Technology 
ENVIRONMENTAL THREATS AND OPPORTUNITIES PROFILE (ETOP) 
FOR STRATEGY: ACQUISITION OF NOVAVAX, 2013 
 
Source: Rowe, Alan, J., Mason, Richard O.,Dickel, Karl E., Mann, Richard B., Mockler. Robert J., Strategic 
Management- A Methodological Approach. 4th Ed. 1999, Reading, MA: Addison - Wesley. p.115.   
Mann and Seshan, Strategy for the 21st Century. IBT Global, Edition 6, 2012. p.75-81  
Factors Impact+of+Factor
Importance+of+
Factor
Environmental+
Threat/Opportunity Rank
Competition )4 9 )36 1
Politics )3 8 )24 2
Energy 2 4 8 3
Economics 2 6 12 4
Spirit:/:Ethics 3 5 15 5
Ecology 3 5 15 6
International 3 7 21 7
Social 4 9 36 8
Technology 5 10 50 9
Total:ETOP:Score:=: 97
Impact:is:ranked:from:)5:(strongly:negative):to:+5:(strongly:positive).
Importance:if:ranked:from:1:(unimportant):to:10:(very:important).
Comments: Competition:is:the:greatest:Threat:for:Merck's:acquisition:of:Novavax,:due:to:the:
saturation:of:other:biotechnology:competitors,:especially:those:developing:pandemic:
and:seasonal:influenza:vaccines.:Politics:is:the:second:biggest:Threat:because:of:strict:
regulations:by:the:FDA:to:ensure:drug:safety:and:effectiveness.:However,:the:
government:has:shown:certain:support:for:the:development:of:pandemic:influenza:
vaccines.:Technology:is:the:biggest:Opportunity,:as:Novavax:will:provide:Merck:with:
innovative:Virus)Like:Particle:technology:to:develop:recombinant:pandemic:and:
seasonal:influenza:vaccines.:This:technology:may:allow:Merck:to:elaborate:effective:
and:safe:influenza:vaccines,:among:other:types:of:vaccines:based:on:such:technology.:
Social:factors:are:the:second:biggest:Opportunity:as:there:is:an:increase:in:population,:
which:is:prone:to:be:infected:by:the:influenza:virus,:especially:the:elderly:and:the:
children.
CRITICAL ISSUES 
•  Merck does not currently have a program devoted to Biotechnology and would 
benefit from the acquisition of a company that would provide a product pipeline in 
the Biotechnology Industry 
RECOMMENDED STRATEGIES 
•  For Merck, its researchers want to develop universal flu vaccines that go beyond 
cellular immunity and protection from challenge,3 as well as Seasonal influenza 
vaccines that have clinical data demonstrating differentiation from marketed 
products  
JUSTIFICATION 
•  Novavax, Inc. has technological advances that have allowed it to make 
breakthroughs in gene therapy techniques that would open up Merck to entirely 
new product lines.  
 
3Staff Writer. “Vaccine – Areas of Interest”. Merck Online. 2013. Internet: http://www.merck.com/licensing/
areas-of-interest/vaccines.html. Accessed 26 July 2013.  
IMPLEMENTATION PLAN 
•  Investment from Merck’s Research and Development department would allow 
Novavax to build more of its smaller facilities, which due to its manufacturing in 
single-use bioreactor systems the economically sized labs can be distributed to 
regions that need a local supply of influenza vaccine.4  
•  A Novavax VLP vaccine plant capacity of 75 to 100 MM doses could be built and 
commissioned for $35-40 MM within 24 months. 
4Staff Writer. “Facilities”. Novavax Online. 2013. Internet: http://www.novavax.com/go.cfm?do=Page.View&pid=96. Accessed 20 July 2013. 
 5Staff Writer. “GE Healthcare”. Novavax Online. 2013. Internet: http://www.novavax.com/go.cfm?do=Page.View&pid=9. Accessed 21 July 2013.  
FINANCIAL ANALYSIS 
CONCLUSION 
•  The potential acquisition strategy would be beneficial to Merck  
 
•  There are Potential Difficulties: 
•  Control, Adaptability, and Organization  
•  Work Load 
 
•  Merck should take a Competitive approach 
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